type 2 diabetes
Conditions
Interventions
canagliflozin treatment group:canagliflozin 100mg qd
metformin treatment group:increased dose of metformin
Sponsors
Peking University People's Hospital
Eligibility
Sex/Gender
All
Age
50 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Men and women aged 50-80 years with poor glycemic control with metformin monotherapy (metformin dose 0.5-1g/d, 7.5%<HbA1c%<9.5%, 7mmol/L<FBG<15mmol/L); 2. No SGLT2 inhibitors, glucagon-like peptide 1 receptor agonists or dipeptidyl peptidase 4 inhibitors were used; 3. Clinically Probable AD according to the National Institute of Neurology, Dyslexic and Stroke -- Institute of Alzheimer's Disease and Related Disorders diagnostic criteria (Probable AD, diagnosis requires pathological evidence); 4. The score of simple mental state is more than 15 points, with the ability to give informed consent; 5. The modified Haschin ischemia Index score was 4 or less to exclude the possibility of ischemic dementia; 6. After evaluation by the researcher, they can cooperate to complete relevant tests in the study, or complete face-to-face follow-up or telephone follow-up with accompanying relatives/guardians.
Exclusion criteria
Exclusion criteria: 1. There are contraindications to the use of cagelin or metformin; 2. Suffering from other neurological diseases other than AD that may affect cognitive function; 3. MRI/CT indicates cerebrovascular disease and is related to dementia, or is diagnosed as vascular dementia; 4. Diagnose serious mental diseases (such as depression) according to the fourth edition of the Diagnostic and Statistical Manual for Patients with Mental Disorders (DSM-IV); 5. Those who have a history of epilepsy and may cause cognitive impairment; 6. Suffering from serious systemic diseases may lead to the deterioration of the physical condition of the subject during the study or the failure to ensure the safety of the subject; 7. Have suffered from myocardial infarction or stroke in the past 1 year, and have been diagnosed with malignant tumor in the past 5 years; 8. Alcohol or drug abuse in recent 2 years; 9. Taking antiepileptic and antiparkinsonian drugs; 10. Acetylcholinesterase inhibitor drugs or memantine have been used but have not been used stably for more than 2 months, or have not been stopped for 2 months; 11. Participated in other AD clinical research and received anti AD experimental drug treatment in recent 1 year; 12. There are contraindications of MRI or CT examination
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| iADRS score; | — |
Secondary
| Measure | Time frame |
|---|---|
| ADAS-Cog13 score;CDR-SB score;MMSE score;ADCS-iADL score; | — |
Countries
China
Contacts
Public ContactXiaoling Cai
Department of Endocrinology, Peking University People's Hospital
Outcome results
None listed